Trial Profile
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Aug 2022
Price :
$35
*
At a glance
- Drugs Encequidar+paclitaxel (Primary) ; HM 30181A (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Athenex
- 01 Jul 2022 The maximum-tolerated dose of Oraxol, determined to be 270 mg daily x 5 days per week per protocol definition as per results published in the Cancer Chemotherapy and Pharmacology
- 01 Jul 2022 Results published in the Cancer Chemotherapy and Pharmacology
- 04 Jun 2018 According to an Athenex media release, data will be presented at the American Society of Clinical Oncology (ASCO) Meeting 2018.